Pentixapharm launches €20.4M rights issue to fund Phase 3 hypertension trial
What's the deal? German biotech Pentixapharm has resolved on a rights issue to raise up to €20.4 million by issuing up to 11,020,212 new shares.
Major shareholder Eckert Wagniskapital, which holds just under 36% of the company, has committed to fully exercise its subscription rights.
Existing shareholders can subscribe at a ratio of nine shares to four new ones, priced at €1.85 each — a roughly 21% discount to the June 30 closing price.
Why now? Pentixapharm needs capital to fund key steps of its PANDA Phase 3 study, which evaluates its lead CXCR4-targeted diagnostic in patients with difficult-to-control hypertension caused by primary aldosteronism.
The company also plans to expand in the US market and strengthen its manufacturing and supply infrastructure.
The subscription period is expected to run from July 7 to July 21, 2026, with BankM accompanying the offering. After costs, net proceeds should reach roughly €19.8 million.
What could go wrong? The raise assumes full placement of all new shares. If shareholders don't take up their rights, unsubscribed shares would be offered to select qualified investors in a private placement.
The 21% discount signals the company had to sweeten the deal to attract capital, and a Phase 3 trial carries significant clinical and regulatory risk.
The signal: Pentixapharm sits at breakout stage, aiming to improve the lives of patients through targeted molecular diagnostics and therapy rooted in nuclear medicine — and getting a CXCR4-targeted diagnostic through Phase 3 is a capital-intensive proving ground for that thesis. Rather than chase a fresh institutional round in a cautious biotech funding market, the company is leaning on its shareholder base, with lead backer Eckert Wagniskapital's full participation anchoring the raise.
Read more: EQS News
Image credit: NavyMedicine
